Inscopix CEO and leadership

Mark Schnitzer is a co-founder of Inscopix, Inc. and its Chief Scientist. He is an Associate Professor of Biology and Applied Physics at Stanford University and is an Investigator of the Howard Hughes Medical Institute. His research concerns the innovation of novel optical imaging technologies and their use in the pursuit of understanding neural circuits. Mark received his M.A. and Ph.D., both in Physics, from Princeton University in 1994 and 1999, respectively. He graduated summa cum laude from Harvard University in 1992 with an A.B. in Physics. Mark is the recipient of several honors and awards, including the 2010 Allen Distinguished Investigator Award, and the 2007 NIH Director’s Pioneer Award.

Heather Robertt is a Chief People Officer at Inscopix.

David joins Inscopix from CNS-focused drug development company Cerevel Therapeutics, where as a founding individual and Vice President of Chemistry had responsibility for intellectual property, and co-led several late-stage clinical programs.During the past eight years, Dr. Gray has been spearheading clinical programs aimed to create improved motor symptom therapies in Parkinson’s disease and treatments for specific cognitive and motivational deficits associated with schizophrenia, Alzheimer’s and other CNS diseases. He led the early research and then the clinical development of a series of D1 partial agonists which include tavapadon, currently in Ph3. He is active in several patient and pre-competitive CNS research communities and has over 50 peer reviewed publications spanning a wide variety of scientific disciplines. David holds a PhD in organic chemistry from The Scripps Research Institute, following which he had a illustrious career at Pfizer, starting as a medicinal chemist then transitioning to leadership roles in the CNS biology department where his group was responsible for human-relevant assay development and translational neuroscience in the areas of depression, schizophrenia, Alzheimer’s and Parkinson’s.

Martin joined Inscopix in March 2021 as Chief Commercial Officer. Prior to that, he spent 8 years at Danaher Corporation, first as VP of Strategy and Marketing followed by VP of New Product Generation and Strategy both at Molecular Devices before becoming VP of Innovation for the Life Sciences Instrumentation group which includes Beckman, Sciex, Leica Microsystems and Molecular Devices. Before that, Martin spent over 12 years with different start-ups including Ciphergen (President of Tools Business), PrimeraDx (CEO), MiraDx (CEO) and Applied BioCode (CEO). During this period, he successfully raised >$50M in capital and was a member of the Ciphergen IPO team. Preceding this, Martin had several roles of increasing responsibility at Agilent during his 10 year employment. He held roles in both Germany and the USA. He worked in marketing for HPLC, Mass Spectrometry and other analytical platforms and ran R&D for the newly established DNA Microarray group. Martin started his career at Cytiva (then known as Pharmacia) in The Netherlands, followed by a 3 year rotation in Sweden. Martin holds a double BS degree in Clinical and Analytical Chemistry. Martin is passionate about innovation in the neuroscience space, in particular focused on psychiatric disorders and addiction.

Mark Schnitzer is a co-founder of Inscopix, Inc. and its Chief Scientist. He is an Associate Professor of Biology and Applied Physics at Stanford University and is an Investigator of the Howard Hughes Medical Institute. His research concerns the innovation of novel optical imaging technologies and their use in the pursuit of understanding neural circuits. Mark received his M.A. and Ph.D., both in Physics, from Princeton University in 1994 and 1999, respectively. He graduated summa cum laude from Harvard University in 1992 with an A.B. in Physics. Mark is the recipient of several honors and awards, including the 2010 Allen Distinguished Investigator Award, and the 2007 NIH Director’s Pioneer Award.

Mark Schnitzer is a co-founder of Inscopix, Inc. and its Chief Scientist. He is an Associate Professor of Biology and Applied Physics at Stanford University and is an Investigator of the Howard Hughes Medical Institute. His research concerns the innovation of novel optical imaging technologies and their use in the pursuit of understanding neural circuits. Mark received his M.A. and Ph.D., both in Physics, from Princeton University in 1994 and 1999, respectively. He graduated summa cum laude from Harvard University in 1992 with an A.B. in Physics. Mark is the recipient of several honors and awards, including the 2010 Allen Distinguished Investigator Award, and the 2007 NIH Director’s Pioneer Award.